Cita APA (7a ed.)

Zabaleta, N., Barberia, M., Martin-Higueras, C., Zapata-Linares, N., Betancor, I., Rodriguez, S., . . . Rodriguez-Madoz, J. R. (2018). CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I. Nature Portfolio.

Cita Chicago Style (17a ed.)

Zabaleta, Nerea, et al. CRISPR/Cas9-mediated Glycolate Oxidase Disruption Is an Efficacious and Safe Treatment for Primary Hyperoxaluria Type I. Nature Portfolio, 2018.

Cita MLA (8a ed.)

Zabaleta, Nerea, et al. CRISPR/Cas9-mediated Glycolate Oxidase Disruption Is an Efficacious and Safe Treatment for Primary Hyperoxaluria Type I. Nature Portfolio, 2018.